• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule.

作者信息

Suzuki Shiho, Suzuki Keisuke, Shiina Tomohiko, Kobayashi Saro, Shioda Mukuto, Hirata Koichi

机构信息

Department of Neurology, Dokkyo Medical University, Japan.

Department of Neurology, Dokkyo Medical University, Japan.

出版信息

J Neurol Sci. 2023 Dec 15;455:122786. doi: 10.1016/j.jns.2023.122786. Epub 2023 Nov 13.

DOI:10.1016/j.jns.2023.122786
PMID:37993359
Abstract
摘要

相似文献

1
Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule.根据患者偏好的给药方案，将降钙素基因相关肽单克隆抗体的给药频率从每月一次改为每季度一次使用fremanezumab。
J Neurol Sci. 2023 Dec 15;455:122786. doi: 10.1016/j.jns.2023.122786. Epub 2023 Nov 13.
2
Response to letter: "Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule" by Suzuki et al.对铃木等人所著信件《基于患者偏好的给药方案，从每月一次降钙素基因相关肽单克隆抗体转换为每季度一次的夫雷西尤单抗》的回复
J Neurol Sci. 2023 Dec 15;455:122785. doi: 10.1016/j.jns.2023.122785. Epub 2023 Nov 13.
3
Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.在发作性和慢性偏头痛患者中，使用 fremanezumab 治疗后头痛的严重程度和持续时间降低。
Headache. 2021 Jun;61(6):916-926. doi: 10.1111/head.14127. Epub 2021 Jun 11.
4
Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan.在日本，每月和每季度注射一次fremanezumab治疗偏头痛患者的真实世界经验。
Front Neurol. 2023 Jul 6;14:1220285. doi: 10.3389/fneur.2023.1220285. eCollection 2023.
5
Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials.每月与每季度使用 fremanezumab 预防偏头痛：来自随机对照试验的系统评价和荟萃分析。
Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. doi: 10.1007/s00210-020-02009-7. Epub 2020 Nov 2.
6
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.年龄和性别对难治性偏头痛患者接受 fremanezumab 疗效的影响：随机、安慰剂对照、3b 期 FOCUS 研究的结果。
J Headache Pain. 2021 Dec 18;22(1):152. doi: 10.1186/s10194-021-01336-1.
7
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.季度或月度给药频次下无氟麦角隐亭出现“时效减退”现象：一项随机长期研究的亚组分析。
Headache. 2020 Nov;60(10):2431-2443. doi: 10.1111/head.13994. Epub 2020 Oct 28.
8
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.氟雷马尼单抗对比安慰剂用于预防阵发性偏头痛的疗效：一项随机临床试验。
JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.
9
Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.接受 fremanezumab 治疗的偏头痛患者的治疗获益：两项安慰剂对照试验的事后应答者分析结果。
J Headache Pain. 2021 Jan 7;22(1):2. doi: 10.1186/s10194-020-01212-4.
10
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.在 FOCUS 三期研究中，对 2 至 4 种偏头痛预防性药物治疗 6 个月后反应不足的发作性和慢性偏头痛患者，评估 fremanezumab 的疗效和安全性。
J Headache Pain. 2021 Jul 10;22(1):68. doi: 10.1186/s10194-021-01279-7.

引用本文的文献

1
Efficacy and Safety of Switching between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review.抗降钙素基因相关肽单克隆抗体之间转换的疗效与安全性：一项详细的月度及长期随访研究与文献综述
Intern Med. 2025 Jul 15;64(14):2114-2123. doi: 10.2169/internalmedicine.4360-24. Epub 2025 Jan 3.